ScienceGate
Advanced Search
Author Search
Journal Finder
Blog
Sign in / Sign up
ScienceGate
Search
Author Search
Journal Finder
Blog
Sign in / Sign up
Necitumumab plus Gemcitabine and Cisplatin as First-Line Therapy in Patients with Stage IV EGFR- Expressing Squamous Non-Small-Cell Lung Cancer: German Subgroup Data from an Open-Label, Randomized Controlled Phase 3 Study (SQUIRE)
Oncology Research and Treatment
◽
10.1159/000448085
◽
2016
◽
Vol 39
(9)
◽
pp. 539-547
◽
Cited By ~ 7
Author(s):
Martin Reck
◽
Michael Thomas
◽
Cornelia Kropf-Sanchen
◽
Jörg Mezger
◽
Mark A. Socinski
◽
...
Keyword(s):
Stage Iv
◽
Small Cell
◽
Small Cell Lung
◽
First Line
◽
Open Label
◽
Phase 3
◽
Randomized Controlled
◽
First Line Therapy
◽
Line Therapy
◽
Gemcitabine And Cisplatin
Download Full-text
Related Documents
Cited By
References
Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial
The Lancet Oncology
◽
10.1016/s1470-2045(15)00021-2
◽
2015
◽
Vol 16
(7)
◽
pp. 763-774
◽
Cited By ~ 252
Author(s):
Nick Thatcher
◽
Fred R Hirsch
◽
Alexander V Luft
◽
Aleksandra Szczesna
◽
Tudor E Ciuleanu
◽
...
Keyword(s):
Stage Iv
◽
Small Cell
◽
Small Cell Lung
◽
First Line
◽
Open Label
◽
Phase 3
◽
First Line Therapy
◽
Line Therapy
◽
Randomised Controlled
◽
Gemcitabine And Cisplatin
Download Full-text
Necitumumab plus pemetrexed and cisplatin as first-line therapy in patients with stage IV non-squamous non-small-cell lung cancer (INSPIRE): an open-label, randomised, controlled phase 3 study
The Lancet Oncology
◽
10.1016/s1470-2045(15)70046-x
◽
2015
◽
Vol 16
(3)
◽
pp. 328-337
◽
Cited By ~ 75
Author(s):
Luis Paz-Ares
◽
Jörg Mezger
◽
Tudor E Ciuleanu
◽
Jürgen R Fischer
◽
Joachim von Pawel
◽
...
Keyword(s):
Lung Cancer
◽
Stage Iv
◽
Small Cell
◽
Small Cell Lung
◽
First Line
◽
Open Label
◽
Phase 3
◽
First Line Therapy
◽
Line Therapy
◽
Randomised Controlled
Download Full-text
A phase III, randomized, open-label trial of nivolumab (anti-PD-1; BMS-936558, ONO-4538) versus investigator's choice chemotherapy (ICC) as first-line therapy for stage IV or recurrent PD-L1+ non-small cell lung cancer (NSCLC).
Journal of Clinical Oncology
◽
10.1200/jco.2014.32.15_suppl.tps8128
◽
2014
◽
Vol 32
(15_suppl)
◽
pp. TPS8128-TPS8128
◽
Cited By ~ 4
Author(s):
David Paul Carbone
◽
Mark A. Socinski
◽
Allen C. Chen
◽
Prabhu Bhagavatheeswaran
◽
Martin Reck
◽
...
Keyword(s):
Lung Cancer
◽
Stage Iv
◽
Small Cell
◽
Phase Iii
◽
Small Cell Lung
◽
First Line
◽
Open Label
◽
First Line Therapy
◽
Line Therapy
◽
Open Label Trial
Download Full-text
Efficacy and Safety of First-Line Necitumumab Plus Gemcitabine and Cisplatin Versus Gemcitabine and Cisplatin in East Asian Patients with Stage IV Squamous Non-small Cell Lung Cancer: A Subgroup Analysis of the Phase 3, Open-Label, Randomized SQUIRE Study
Cancer Research and Treatment
◽
10.4143/crt.2016.423
◽
2017
◽
Vol 49
(4)
◽
pp. 937-946
◽
Cited By ~ 5
Author(s):
Keunchil Park
◽
Eun Kyung Cho
◽
Maximino Bello
◽
Myung-Ju Ahn
◽
Sumitra Thongprasert
◽
...
Keyword(s):
Stage Iv
◽
Small Cell
◽
Efficacy And Safety
◽
Small Cell Lung
◽
First Line
◽
Open Label
◽
Phase 3
◽
Asian Patients
◽
East Asian Patients
◽
Gemcitabine And Cisplatin
Download Full-text
195TiP A phase 3, randomized, double-blind study of epacadostat plus pembrolizumab vs pembrolizumab as first-line therapy for metastatic non-small cell lung cancer (mNSCLC) expressing high PD-L1 levels (ECHO-305/KEYNOTE-654)
Journal of Thoracic Oncology
◽
10.1016/s1556-0864(18)30468-4
◽
2018
◽
Vol 13
(4)
◽
pp. S116-S117
Author(s):
L. Paz-Ares
◽
S. Rubin
◽
Y. Zhao
◽
L. Xu
◽
A. Samkari
◽
...
Keyword(s):
Lung Cancer
◽
Small Cell Lung Cancer
◽
Small Cell
◽
Double Blind Study
◽
Small Cell Lung
◽
First Line
◽
Phase 3
◽
Double Blind
◽
First Line Therapy
◽
Line Therapy
Download Full-text
Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study
The Lancet Oncology
◽
10.1016/s1470-2045(14)70381-x
◽
2014
◽
Vol 15
(11)
◽
pp. 1236-1244
◽
Cited By ~ 383
Author(s):
Takashi Seto
◽
Terufumi Kato
◽
Makoto Nishio
◽
Koichi Goto
◽
Shinji Atagi
◽
...
Keyword(s):
Small Cell
◽
Egfr Mutations
◽
Phase 2
◽
Small Cell Lung
◽
First Line
◽
Open Label
◽
Multicentre Phase
◽
First Line Therapy
◽
Line Therapy
◽
Phase 2 Study
Download Full-text
Randomized controlled trial of lobaplatin plus etoposide vs. cisplatin plus etoposide as first‑line therapy in patients with extensive‑stage small cell lung cancer
Oncology Letters
◽
10.3892/ol.2019.10125
◽
2019
◽
Cited By ~ 1
Author(s):
Ying Cheng
◽
Yun Fan
◽
Xiaoqing Liu
◽
Yunpeng Liu
◽
Jiwei Liu
◽
...
Keyword(s):
Lung Cancer
◽
Randomized Controlled Trial
◽
Controlled Trial
◽
Small Cell
◽
Small Cell Lung
◽
First Line
◽
Randomized Controlled
◽
First Line Therapy
◽
Line Therapy
◽
Extensive Stage
Download Full-text
P3-135: Results of an open-label, Phase II trial of nanoparticle albumin bound paclitaxel (nab-paclitaxel), carboplatin, and bevacizumab as first-line therapy in patients with advanced non-squamous non-small cell lung cancer (NSCLC)
Journal of Thoracic Oncology
◽
10.1097/01.jto.0000284110.26459.89
◽
2007
◽
Vol 2
(8)
◽
pp. S736-S737
Author(s):
Craig Reynolds
◽
David Barrera
◽
Duy Quoc Vu
◽
Robert Jotte
◽
Alexander I. Spira
◽
...
Keyword(s):
Lung Cancer
◽
Small Cell Lung Cancer
◽
Phase Ii Trial
◽
Small Cell
◽
Small Cell Lung
◽
First Line
◽
Open Label
◽
First Line Therapy
◽
Line Therapy
◽
Open Label Phase
Download Full-text
Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line treatment for stage IV squamous non-small cell lung cancer: A phase 1b and randomized, open-label, multicenter, phase 2 trial in Japan
Lung Cancer
◽
10.1016/j.lungcan.2019.01.005
◽
2019
◽
Vol 129
◽
pp. 55-62
◽
Cited By ~ 6
Author(s):
Satoshi Watanabe
◽
Hiroshige Yoshioka
◽
Hiroshi Sakai
◽
Katsuyuki Hotta
◽
Mitsuhiro Takenoyama
◽
...
Keyword(s):
Stage Iv
◽
Small Cell
◽
Phase 2
◽
Small Cell Lung
◽
First Line
◽
Open Label
◽
Phase 2 Trial
◽
Multicenter Phase
◽
Phase 1B
◽
Gemcitabine And Cisplatin
Download Full-text
A phase III, randomized, open-label, multicenter study of SHR-1210 (anti-PD-1 antibody) in combination with pemetrexed and carboplatin as first line therapy in subjects with advanced/metastatic non-squamous non-small cell lung cancer
Annals of Oncology
◽
10.1093/annonc/mdy292.126
◽
2018
◽
Vol 29
◽
pp. viii545
◽
Cited By ~ 1
Author(s):
F. Wu
◽
G. Gao
◽
C. Zhou
◽
X. Kang
◽
Y. Zhou
Keyword(s):
Lung Cancer
◽
Small Cell Lung Cancer
◽
Multicenter Study
◽
Small Cell
◽
Phase Iii
◽
Small Cell Lung
◽
First Line
◽
Open Label
◽
First Line Therapy
◽
Line Therapy
Download Full-text
Sign in / Sign up
Close
Export Citation Format
Close
Share Document
Close